OKYO Pharma (OKYO) Competitors $2.06 -0.14 (-6.14%) As of 09:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKYO vs. FDMT, ENGN, AMRN, IMAB, TECX, SCPH, ALDX, LFCR, KRRO, and RAPTShould you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include 4D Molecular Therapeutics (FDMT), enGene (ENGN), Amarin (AMRN), I-Mab (IMAB), Tectonic Therapeutic (TECX), scPharmaceuticals (SCPH), Aldeyra Therapeutics (ALDX), Lifecore Biomedical (LFCR), Korro Bio (KRRO), and Rapt Therapeutics (RAPT). These companies are all part of the "pharmaceutical products" industry. OKYO Pharma vs. Its Competitors 4D Molecular Therapeutics enGene Amarin I-Mab Tectonic Therapeutic scPharmaceuticals Aldeyra Therapeutics Lifecore Biomedical Korro Bio Rapt Therapeutics 4D Molecular Therapeutics (NASDAQ:FDMT) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do institutionals and insiders hold more shares of FDMT or OKYO? 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is FDMT or OKYO more profitable? OKYO Pharma has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. OKYO Pharma's return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular Therapeutics-594,375.81% -40.15% -36.43% OKYO Pharma N/A N/A N/A Which has stronger valuation & earnings, FDMT or OKYO? OKYO Pharma has lower revenue, but higher earnings than 4D Molecular Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$40K9,602.69-$160.87M-$3.53-2.33OKYO PharmaN/AN/A-$4.71MN/AN/A Which has more volatility and risk, FDMT or OKYO? 4D Molecular Therapeutics has a beta of 2.86, suggesting that its share price is 186% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Do analysts rate FDMT or OKYO? 4D Molecular Therapeutics currently has a consensus target price of $30.40, indicating a potential upside of 269.60%. OKYO Pharma has a consensus target price of $7.00, indicating a potential upside of 238.98%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe 4D Molecular Therapeutics is more favorable than OKYO Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70OKYO Pharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to FDMT or OKYO? In the previous week, OKYO Pharma had 15 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 16 mentions for OKYO Pharma and 1 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.24 beat OKYO Pharma's score of 0.32 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Overall Sentiment 4D Molecular Therapeutics Positive OKYO Pharma Neutral Summary4D Molecular Therapeutics beats OKYO Pharma on 7 of the 13 factors compared between the two stocks. Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKYO vs. The Competition Export to ExcelMetricOKYO PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.67M$3.15B$5.77B$10.41BDividend YieldN/A2.36%5.68%4.62%P/E RatioN/A20.7676.0626.43Price / SalesN/A393.08520.37168.08Price / CashN/A45.9137.5661.52Price / Book-12.919.8312.766.39Net Income-$4.71M-$52.73M$3.29B$271.13M7 Day Performance-0.24%1.84%0.77%0.93%1 Month Performance-15.02%7.48%4.90%7.52%1 Year Performance108.59%19.92%66.58%30.06% OKYO Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKYOOKYO Pharma2.2648 of 5 stars$2.07-6.1%$7.00+239.0%+108.9%$77.67MN/A0.007News CoverageAnalyst ForecastAnalyst RevisionFDMT4D Molecular Therapeutics2.7612 of 5 stars$6.69-1.6%$30.40+354.4%-26.5%$312.44M$33K-1.90120Positive NewsENGNenGene2.5761 of 5 stars$6.07+1.7%$21.00+246.0%+12.6%$310.21MN/A-3.1931AMRNAmarin0.5801 of 5 stars$14.93flat$12.00-19.6%+32.4%$308.80M$219.36M-4.07360Positive NewsIMABI-Mab2.4348 of 5 stars$3.72+2.8%$7.00+88.2%+220.7%$303.78MN/A0.00380TECXTectonic Therapeutic2.8619 of 5 stars$16.01-3.5%$80.29+401.5%-38.2%$299.55MN/A-3.96120SCPHscPharmaceuticals4.0825 of 5 stars$5.62+0.2%$7.78+38.5%+18.0%$299.55M$36.33M-3.1030Positive NewsALDXAldeyra Therapeutics2.0749 of 5 stars$4.96-2.6%$9.50+91.5%-11.3%$297.10MN/A-5.8410LFCRLifecore Biomedical1.2655 of 5 stars$7.86+2.3%$8.00+1.8%+41.3%$294.04M$128.87M-6.00690KRROKorro Bio1.6871 of 5 stars$31.14-0.7%$86.83+178.8%+10.0%$292.44M$6.28M-3.1970Positive NewsRAPTRapt Therapeutics3.2843 of 5 stars$17.63+1.2%$21.57+22.4%+70.1%$291.57MN/A-1.2480Positive NewsGap Up Related Companies and Tools Related Companies FDMT Alternatives ENGN Alternatives AMRN Alternatives IMAB Alternatives TECX Alternatives SCPH Alternatives ALDX Alternatives LFCR Alternatives KRRO Alternatives RAPT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKYO) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKYO Stock Alerts